Kenvue Inc. $KVUE Shares Sold by Arizona State Retirement System

Arizona State Retirement System cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 526,502 shares of the company’s stock after selling 34,861 shares during the quarter. Arizona State Retirement System’s holdings in Kenvue were worth $9,082,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC raised its holdings in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after purchasing an additional 1,361 shares in the last quarter. NBT Bank N A NY raised its holdings in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in shares of Kenvue in the 3rd quarter valued at $25,000. Golden State Wealth Management LLC raised its holdings in shares of Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after purchasing an additional 1,190 shares in the last quarter. Finally, New England Capital Financial Advisors LLC raised its holdings in shares of Kenvue by 81.4% in the 3rd quarter. New England Capital Financial Advisors LLC now owns 2,563 shares of the company’s stock valued at $42,000 after purchasing an additional 1,150 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 0.0%

NYSE KVUE opened at $17.49 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The firm’s fifty day moving average price is $17.82 and its 200 day moving average price is $17.15. The company has a market capitalization of $33.57 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 3.97 and a beta of 0.61. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.1 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Barclays reduced their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Argus upgraded shares of Kenvue to a “hold” rating in a report on Friday, March 6th. Canaccord Genuity Group raised their price objective on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Citigroup reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Finally, UBS Group dropped their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.